Leonteq Securities AG Purchases New Position in Amgen Inc. $AMGN

Leonteq Securities AG purchased a new stake in Amgen Inc. (NASDAQ:AMGN) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 2,473 shares of the medical research company’s stock, valued at approximately $809,000.

Other institutional investors also recently bought and sold shares of the company. Robeco Institutional Asset Management B.V. grew its holdings in shares of Amgen by 10.0% during the fourth quarter. Robeco Institutional Asset Management B.V. now owns 481,453 shares of the medical research company’s stock worth $157,584,000 after purchasing an additional 43,884 shares during the last quarter. Curtis Advisory Group LLC purchased a new position in shares of Amgen during the fourth quarter worth about $1,669,000. Jones Financial Companies Lllp grew its holdings in shares of Amgen by 18.2% during the third quarter. Jones Financial Companies Lllp now owns 39,778 shares of the medical research company’s stock worth $10,888,000 after purchasing an additional 6,115 shares during the last quarter. Adell Harriman & Carpenter Inc. grew its holdings in shares of Amgen by 7.9% during the fourth quarter. Adell Harriman & Carpenter Inc. now owns 22,008 shares of the medical research company’s stock worth $7,204,000 after purchasing an additional 1,609 shares during the last quarter. Finally, Lockheed Martin Investment Management Co. purchased a new position in shares of Amgen during the third quarter worth about $2,624,000. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Amgen Price Performance

Shares of AMGN opened at $339.30 on Friday. Amgen Inc. has a fifty-two week low of $267.83 and a fifty-two week high of $391.29. The company has a market capitalization of $183.12 billion, a price-to-earnings ratio of 23.61, a price-to-earnings-growth ratio of 3.39 and a beta of 0.44. The firm has a 50-day simple moving average of $345.10 and a 200-day simple moving average of $344.38. The company has a debt-to-equity ratio of 5.65, a quick ratio of 1.01 and a current ratio of 1.26.

Amgen (NASDAQ:AMGN) last announced its earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, topping the consensus estimate of $4.77 by $0.38. The business had revenue of $8.62 billion during the quarter, compared to the consensus estimate of $8.58 billion. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The business’s quarterly revenue was up 5.8% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $4.90 earnings per share. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. On average, equities research analysts anticipate that Amgen Inc. will post 22.37 earnings per share for the current year.

Amgen Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be given a $2.52 dividend. The ex-dividend date is Friday, May 15th. This represents a $10.08 dividend on an annualized basis and a yield of 3.0%. Amgen’s dividend payout ratio (DPR) is presently 70.15%.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on AMGN shares. Freedom Capital raised Amgen from a “hold” rating to a “strong-buy” rating in a report on Thursday, May 7th. The Goldman Sachs Group raised their price objective on Amgen from $415.00 to $425.00 and gave the stock a “buy” rating in a report on Friday, May 1st. Citigroup increased their target price on shares of Amgen from $315.00 to $345.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 4th. Oppenheimer set a $400.00 target price on shares of Amgen and gave the stock an “outperform” rating in a research note on Thursday, January 29th. Finally, TD Cowen reiterated a “buy” rating on shares of Amgen in a research note on Wednesday, February 4th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, fourteen have issued a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $355.19.

Insider Buying and Selling

In related news, SVP Nancy A. Grygiel sold 1,237 shares of the firm’s stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $323.73, for a total value of $400,454.01. Following the completion of the sale, the senior vice president owned 7,009 shares in the company, valued at $2,269,023.57. This trade represents a 15.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.85% of the stock is currently owned by insiders.

Key Headlines Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen expanded its lung cancer pipeline by launching a phase 1b study testing a tarlatamab combination in small cell lung cancer, which could improve the company’s oncology growth prospects if the data are encouraging. Amgen Expands Lung Cancer Pipeline With New Tarlatamab Combo Study
• Positive Sentiment: Several reports highlighted Amgen as a long-term value/dividend and pipeline story, citing upside potential and analyst support such as an Overweight rating from Piper Sandler, reinforcing confidence in the company’s revenue growth outlook. Why Wall Street Thinks This Dividend Stock Could Jump 30%
• Positive Sentiment: Amgen shareholders reaffirmed the board, executive pay and auditors, which signals governance stability and removes a potential overhang. Amgen Shareholders Reaffirm Board, Pay and Auditors
• Neutral Sentiment: Amgen appointed Thomas Dittrich as chief financial officer, a management update that should be watched for any strategic or capital-allocation changes, but is not clearly a near-term stock catalyst. CFOs On the Move: Week ending May 22
• Negative Sentiment: Investor focus remains on safety concerns around Tavneos after reported patient deaths in Japan prompted restrictions on new prescriptions and raised the risk of withdrawal requests in the U.S., creating a potential earnings and sentiment headwind for Amgen. A Look At Amgen (AMGN) Valuation As Tavneos Safety Concerns And Withdrawal Requests Escalate
• Negative Sentiment: News that doctors in Japan could again prescribe Tavneos to new patients only partially eases concerns, because the drug still carries liver-injury warnings and the broader safety controversy may continue to pressure sentiment. Doctors in Japan can again prescribe an Amgen rare-disease drug to new patients, reversing a recommendation made only days ago following 20 deaths

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.